102 related articles for article (PubMed ID: 24166527)
1. When inoperable becomes operable?
Mroczkowski P; Seidensticker M
J Clin Oncol; 2013 Dec; 31(35):4474. PubMed ID: 24166527
[No Abstract] [Full Text] [Related]
2. Treatment of metastatic colon cancer: "the times they are A-changing".
Kemeny NE
J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
[No Abstract] [Full Text] [Related]
3. Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.
Sunakawa Y; Takahashi T; Ichikawa W; Shimada K; Sasaki Y
J Clin Oncol; 2013 Dec; 31(35):4473. PubMed ID: 24166514
[No Abstract] [Full Text] [Related]
4. Surgery: Cetuximab--an option for unresectable CRC liver metastases.
Laurent-Puig P; Benhaim L
Nat Rev Clin Oncol; 2013 Jul; 10(7):374-5. PubMed ID: 23736647
[No Abstract] [Full Text] [Related]
5. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
6. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and efficacy: are we nearly there yet?
Russo A; Rizzo S
Ann Oncol; 2011 Jul; 22(7):1469-1470. PubMed ID: 21551003
[No Abstract] [Full Text] [Related]
8. Hurdles and complexities of codon 13 KRAS mutations.
Morelli MP; Kopetz S
J Clin Oncol; 2012 Oct; 30(29):3565-7. PubMed ID: 22927534
[No Abstract] [Full Text] [Related]
9. When more is worse in clinical research and clinical practice.
Tassinari D; Tombesi P; Sartori S
Am J Clin Oncol; 2010 Aug; 33(4):424. PubMed ID: 20689366
[No Abstract] [Full Text] [Related]
10. Managing advanced colorectal cancer: have we reached the PEAK with current therapies?
Wolpin BM; Bass AJ
J Clin Oncol; 2014 Jul; 32(21):2200-2. PubMed ID: 24934780
[No Abstract] [Full Text] [Related]
11. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
Lieu CH; Messersmith WA
JAMA; 2017 Jun; 317(23):2376-2378. PubMed ID: 28632850
[No Abstract] [Full Text] [Related]
12. Adjuvant therapy after hepatectomy for colorectal metastases.
Fong Y
Lancet Oncol; 2014 May; 15(6):544-5. PubMed ID: 24807857
[No Abstract] [Full Text] [Related]
13. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
14. Reply to Y. Sunakawa et al and P. Mroczkowski et al.
Ye LC; Zhong YS; Lin Q; Xu J
J Clin Oncol; 2013 Dec; 31(35):4474-5. PubMed ID: 24166525
[No Abstract] [Full Text] [Related]
15. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab in metastatic colorectal cancer.
Wolf I; Golan T; Shani A; Aderka D
Lancet Oncol; 2010 Apr; 11(4):313-4; author reply 314. PubMed ID: 20359660
[No Abstract] [Full Text] [Related]
17. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
18. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Chu E
Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
[No Abstract] [Full Text] [Related]
20. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
